Well-differentiated (WD) and dedifferentiated (DD) liposarcomas (LPS) are characterized by cyclin-dependent kinase (CDK)4 and mouse double minute 2 homolog (MDM2) amplification. Palbociclib, a selective CDK4/6 inhibitor, demonstrated promising activity in prior phase II trials and is included in the National Comprehensive Cancer Network Compendium for LPS. However, long-term overall survival (OS) data remain limited.
ESMO Open published a clinical update in Oncology on 20 Mar 2026.
The item focuses on Overall survival from the open-label phase II trial of palbociclib in patients with advanced well-differentiated/dedifferentiated liposarcoma.
Review the original article for the full source wording and details.